{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:43Z","timestamp":1793431903134,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.05.034","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:06:06Z","timestamp":1780531566000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Denosumab versus Zoledronic Acid in the Treatment of Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Comparative Study"],"prefix":"10.1016","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4072","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.05.034_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2018.09.013","article-title":"Primary hyperparathyroidism","volume":"38","author":"Silva","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.034_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40618-024-02464-6","article-title":"Prevalence, risk factors and effect of curative parathyroidectomy on nephrocalcinosis in Asian-Indian patients with symptomatic primary hyperparathyroidism","volume":"48","author":"Kumari","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.eprac.2026.05.034_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.115978","article-title":"A thorough evaluation for primary hyperparathyroidism: more than a stone's throw away","volume":"238","author":"Green","year":"2024","journal-title":"Am J Surg"},{"key":"10.1016\/j.eprac.2026.05.034_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjsurg.2021.01.027","article-title":"An institutional experience with primary hyperparathyroidism in the elderly over two decades","volume":"222","author":"O'Sullivan","year":"2021","journal-title":"Am J Surg"},{"key":"10.1016\/j.eprac.2026.05.034_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2025.102449","article-title":"French expert consensus statement on diagnosis and management of primary hyperparathyroidism","volume":"86","author":"Vantyghem","year":"2025","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.eprac.2026.05.034_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoto.2024.1421","article-title":"F18-Choline PET\/CT or MIBI SPECT\/CT in the surgical management of primary hyperparathyroidism: a diagnostic randomized clinical trial","volume":"150","author":"Quak","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.eprac.2026.05.034_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/cen.70088","article-title":"Is parenteral bisphosphonate therapy safe and effective in the management of severe primary hyperparathyroidism prior to parathyroidectomy?","author":"Maarouf","year":"2026","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2026.05.034_bib8","article-title":"Severe hypercalcemia following pembrolizumab therapy: a case report and A literature review","author":"Lazzaroni","year":"2025","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.eprac.2026.05.034_bib9","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1021\/acs.molpharmaceut.2c00644","article-title":"Zoledronic acid implant coating results in local medullary bone growth","volume":"19","author":"Quarterman","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.eprac.2026.05.034_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07728-8","article-title":"First-line [(18)F]F-choline PET\/CT in primary hyperparathyroidism: a cost-effectiveness study from the diagnostic randomized APACH2 trial","author":"Quak","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eprac.2026.05.034_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jbmr\/zjaf195","article-title":"Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease","author":"Sun","year":"2026","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2026.05.034_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka D","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2026.05.034_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044882","article-title":"Effectiveness and safety of denosumab monotherapy in patients with primary hyperparathyroidism: a retrospective study","volume":"104","author":"Okada A","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eprac.2026.05.034_bib14","article-title":"Denosumab Attenuates glucolipotoxicity-induced \u03b2-Cell dysfunction and apoptosis by attenuating RANK\/RANKL signals","volume":"24","author":"Lin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2026.05.034_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26114990","article-title":"RANKL drives bone metastasis in mammary cancer: protective effects of anti-resorptive treatments","volume":"26","author":"Gkikopoulou","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2026.05.034_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis : a target trial emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.05.034_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1210\/clinem\/dgac631","article-title":"A systematic review supporting the Endocrine Society Clinical Practice Guideline on the treatment of hypercalcemia of malignancy in adults","volume":"108","author":"Seisa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.034_bib18","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society","volume":"191","author":"Paccou","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.034_bib19","doi-asserted-by":"crossref","first-page":"e3756","DOI":"10.1210\/clinem\/dgaf107","article-title":"The efficacy and safety of denosumab for treating hypercalcemia in primary hyperparathyroidism: a retrospective study","volume":"110","author":"Song","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.034_bib20","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1245\/s10434-023-13344-3","article-title":"Primary hyperparathyroidism in young adult patients","volume":"30","author":"Gasior","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eprac.2026.05.034_bib21","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.eprac.2022.09.006","article-title":"Withdrawal of denosumab in patients with primary hyperparathyroidism: a Follow-up report of the DENOCINA Study","volume":"28","author":"Leere","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.05.034_bib22","first-page":"516","article-title":"The urinary calcium-magnesium product as a potential indicator of nephrolithiasis in primary hyperparathyroidism","volume":"76","author":"Popow","year":"2025","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.eprac.2026.05.034_bib23","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.034_bib24","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1007\/s12033-023-00931-8","article-title":"Zoledronic acid accelerates bone healing in Carpal navicular fracture via silencing long non-coding RNA growth arrest specificity 5 to modulate MicroRNA-29a-3p expression","volume":"66","author":"Liu","year":"2024","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.eprac.2026.05.034_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116871","article-title":"Peptides as modulators of FPPS enzyme: a multifaceted evaluation from the design to the mechanism of action","volume":"279","author":"Covelli","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.eprac.2026.05.034_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11154-024-09899-5","article-title":"Primary hyperparathyroidism: from guidelines to outpatient clinic","volume":"25","author":"Palermo","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eprac.2026.05.034_bib27","article-title":"Clinical features and treatment of hypophosphatemia and associated complications induced by Phosphaturic mesenchymal tumors: a case series of six patients","volume":"24","author":"Lai","year":"2025","journal-title":"Bone Rep"},{"key":"10.1016\/j.eprac.2026.05.034_bib28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and Management of Primary Hyperparathyroidism: summary statement and Guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:00:37Z","timestamp":1793430037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S1530891X26010268"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.034","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Denosumab versus Zoledronic Acid in the Treatment of Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Comparative Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}